FDA Approves Over-the-Counter CGM for Childhood Obesity Management
The FDA has approved an over-the-counter continuous glucose monitor (CGM) for use in young children, including toddlers as young as two years old, as a tool for childhood obesity management. The approval represents a significant shift in glucose monitoring technology from prescription diabetes management to preventive wellness applications in the pediatric population. Medical experts are evaluating the clinical benefits of real-time glucose data for obesity prevention against potential risks including device-related anxiety, misinterpretation of normal glucose fluctuations in non-diabetic children, and the appropriateness of medical device use in very young children. The approval takes effect immediately with retail availability expected in the coming months.